Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Every FDA drug approval in 2025: Number of new treatments dipped during agency upheaval

Summary
It was a chaotic year at the Food and Drug Administration. Thousands of staff left the agency. Leadership was unstable. Routine drug reviews were delayed, Commissioner Marty Makary reportedly
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

endpoints.newsendpoints.news

2025's huge FDA staff cuts mostly didn't impact new drug review timelines, analysis finds

Despite thousands of FDA staff cuts, retirements and leadership departures in 2025, the agency’s drug reviewers managed to hold the line and meet just about all of its user-fee commitments for new drug reviews. ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Thursday, January 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Silver Spring icon

Silver Spring

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal